10 December 2020
Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors
BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs) aimed at treating people suffering from cystic fibrosis (CF). The Company will receive up to $343,000 in research funding to advance its proprietary 3rd-generation intein platform and develop novel AAVs better suited to target specific cells in the lungs of people with CF.
“We are excited to work together with the Cystic Fibrosis Foundation and look forward to advancing novel gene therapies that can contribute to the development of a cure for cystic fibrosis”, said Miquel Vila-Perelló, co-founder and CEO of Splice Bio.
About Splice Bio
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company has developed a proprietary, 3rd-generation intein platform that addresses two existing limitations of adeno-associated viruses (AAVs) as vectors for gene therapy, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. The company is backed by Ysios Capital, Asabys Partners and Caixa Capital Risc. For additional information, visit www.splice.bio.
